Boston, United States
Galibra Neuroscience, Inc., founded in 2023, is a pioneering gene therapy startup with a focus on addressing brain disorders through a novel approach. They aim to target the delicate balance of brain excitation and inhibition, specifically attending to GABA-related conditions.
Under the guiding slogan, "Balancing Brain Excitation and Inhibition," the company is positioned to make significant strides in the neurotherapeutics industry, although currently, details are sparse regarding their industry partnerships and specific operational base, as their headquarters remain undisclosed.
While they haven't yet attracted outside investment or named investors, Galibra Neuroscience stands as a potential contender for those looking to invest in an innovative field that combines advancing gene therapy with unmet neurological needs. As they develop, tracking their progress could offer valuable insights into the evolving landscape of biotechnology solutions.
